Skip to content
All resources

GLP-1 and metabolic

Mazdutide: GLORY and DREAMS Trial Results and Approval Status

AM

By

· 9 min read

A summary of published research, with citations. It states no amount, schedule or route, and makes no claim about what this compound does in a person. Supplied for laboratory research use only.

On this page · 8 sections
  1. What is mazdutide?
  2. Where is mazdutide approved?
  3. What did the GLORY obesity trials find?
  4. What did the DREAMS diabetes trials find?
  5. How should these results be read?
  6. What trials are still running?
  7. How does mazdutide fit into the pipeline?
  8. Frequently asked questions

Mazdutide (IBI362, LY3305677) is a dual GLP-1 and glucagon receptor agonist developed by Innovent Biologics with Eli Lilly. In June 2025 it received its first approval, in China, for long-term weight management, followed in September 2025 by approval in China for glycaemic control in type 2 diabetes. In the GLORY-1 phase 3 trial, weight change at 48 weeks was −11.0% to −14.0% against +0.3% on placebo. No approval outside China could be confirmed, and it is not authorised in Canada.

Translucent models of the liver and pancreas side by side
Illustration: two organs a dual GLP-1 and glucagon agonist is studied against.

What is mazdutide?

Mazdutide is a single peptide that activates the GLP-1 receptor and the glucagon receptor. It carries two development codes, Eli Lilly's LY3305677 and Innovent's IBI362; Lilly ran its first phase 1 studies under the former, and Innovent ran the Chinese phase 3 trials under the latter. Its Chinese brand name is Xinermei. It belongs to the same design family as survodutide and pemvidutide, and it shares two of retatrutide's three receptors.

Why anyone would agonise the glucagon receptor, a hormone that raises blood glucose, is the subject of glucagon receptor agonists explained. The receptor biology itself is in the GLP-1, GIP and glucagon receptor guide. This page sticks to what mazdutide's own trials measured.

Where is mazdutide approved?

A 2025 drug-development profile by Shirley records two approvals, both in China:

DateJurisdictionApproved use
June 2025ChinaLong-term weight management with diet and physical activity, in adults with a BMI of 28 or more, or 24 or more with a weight-related comorbidity
September 2025ChinaGlycaemic control in adults with type 2 diabetes

Those thresholds are lower than the BMI of 27 and 30 used as entry criteria in Western trials such as survodutide's SYNCHRONIZE programme, a difference to keep in mind when comparing populations.

The same profile lists mazdutide as still under clinical evaluation for fatty liver disease, obstructive sleep apnoea and alcohol use disorder. This article found no approval by the FDA, the EMA or Health Canada. An approval in one country does not carry over to another; each regulator reviews its own dossier, as the article on generic semaglutide in Canada explains for a drug that is authorised here. Health Canada's Drug Product Database is where a Canadian authorisation would appear.

What did the GLORY obesity trials find?

GLORY is the obesity programme. Both published phase 3 trials were run in China by Innovent.

GLORY-1 randomised 610 Chinese adults with a BMI of at least 28, or 24 to 28 with a weight-related condition, to one of two mazdutide dose levels or placebo for 48 weeks. Mean baseline weight was 87.2 kg and BMI 31.1. The primary endpoints were measured at week 32 with a treatment-policy estimand. At week 32, weight change was −10.09% and −12.55% against +0.45% on placebo. By week 48 it was −11.00% and −14.01% against +0.30%, and 35.7% and 49.5% of mazdutide recipients had lost at least 15% of their weight, against 2.0% on placebo. Gastrointestinal events were the most common adverse events and were mostly mild to moderate. Discontinuation because of adverse events was low: 1.5%, 0.5% and 1.0%.

GLORY-2 tested a higher dose level in 462 Chinese adults with a BMI of 30 or more, 16.1% of whom had type 2 diabetes, for 60 weeks. Participants were young: mean age 33.9. Weight change at week 60 was −16.65% with mazdutide against −1.50% with placebo, a difference of −15.15 percentage points. At least 5% weight reduction was reached by 84.3% against 33.1%. The price was gastrointestinal: vomiting in 53.1% against 1.3% on placebo, nausea in 46.9% against 3.2%, and diarrhoea in 39.4% against 6.5%. Adverse events led 2.9% of mazdutide recipients to stop.

A US phase 2 trial, sponsored by Lilly and published in 2026, randomised 179 adults without diabetes at 24 US centres to mazdutide across a wider dose range or placebo. At 32 weeks, using an efficacy estimand, weight change ranged from −7.3% to −18.1% against −0.9% on placebo, with further reductions by 48 weeks. Discontinuation because of adverse events reached 20% at the highest dose level, mainly for gastrointestinal reasons. This is the first published efficacy trial of mazdutide outside China, and it is phase 2.

What did the DREAMS diabetes trials find?

DREAMS is the type 2 diabetes programme, with HbA1c as the primary endpoint.

DREAMS-1 randomised 320 people with type 2 diabetes managed by diet and exercise alone. At week 24, HbA1c fell by 1.57 and 2.15 percentage points on the two mazdutide dose levels against 0.14 on placebo. Weight fell by 5.61% and 7.81% against 1.26%. The most common adverse events were diarrhoea, decreased appetite and nausea.

DREAMS-2 compared mazdutide with an active drug, dulaglutide, in 731 people with type 2 diabetes on background glucose-lowering medicines, for 28 weeks. Both mazdutide dose levels were non-inferior and superior to dulaglutide on HbA1c, but the margins were modest: treatment differences of −0.24 and −0.30 percentage points. The weight differences were larger: −3.78% and −5.76% relative to dulaglutide. Gastrointestinal adverse events were more frequent on mazdutide.

DREAMS-3 is a head-to-head trial against semaglutide in 349 Chinese adults with type 2 diabetes and obesity. Its primary endpoint is a composite: the share reaching both HbA1c below 7.0% and at least 10% weight reduction at week 32. The design and baseline paper was published, and the registry (NCT06184568) lists the trial as completed, but no results paper was found on PubMed by late October 2026.

TrialPopulationComparatorDurationPrimary result
GLORY-1Chinese adults with overweight or obesity; 610Placebo48 weeks (primary at 32)Weight −10.1% and −12.6% vs +0.5% at week 32
GLORY-2Chinese adults with BMI ≥30; 462Placebo60 weeksWeight −16.7% vs −1.5%
US phase 2US adults without diabetes; 179Placebo48 weeks (primary at 32)Weight −7.3% to −18.1% vs −0.9%
DREAMS-1Type 2 diabetes, diet and exercise only; 320Placebo24 weeksHbA1c −1.57 and −2.15 vs −0.14 points
DREAMS-2Type 2 diabetes on background drugs; 731Dulaglutide28 weeksHbA1c −0.24 and −0.30 points vs dulaglutide

How should these results be read?

The populations are mostly Chinese adults. Every phase 3 trial published so far was conducted in China. Body composition, BMI distribution and the threshold at which obesity is diagnosed differ, so a percentage from GLORY-1 is a fact about that population. The US phase 2 trial is a start on the question of how mazdutide performs elsewhere.

Durations are short. GLORY-1's primary endpoint was at 32 weeks, and DREAMS-1 and DREAMS-2 at 24 and 28 weeks. The SYNCHRONIZE trials of survodutide measured at 76 weeks and CagriSema's REDEFINE trials at 68. A 32-week figure placed beside a 72-week one is not a comparison, as the tirzepatide vs eloralintide vs mazdutide article points out.

Placebo groups barely moved. In GLORY-1 the placebo group gained slightly. That makes the treatment difference large and is worth knowing when reading any cross-trial table.

Heart rate needs watching. A 2026 review of glucagon co-agonists by Kushner and Michos concluded that mazdutide and survodutide trials have generally shown heart-rate increases similar to those with GLP-1 agonists alone, with reductions in blood pressure. No cardiovascular outcomes trial of mazdutide was found on ClinicalTrials.gov.

What trials are still running?

Innovent's registered phase 3 programme on ClinicalTrials.gov includes a head-to-head trial against semaglutide in Chinese adults with overweight or obesity and metabolic dysfunction-associated fatty liver disease (NCT06884293), a trial in obstructive sleep apnoea (NCT06931028), a trial in adolescents (NCT07255209), and one in people with hypertension and overweight (NCT07469800). Lilly has completed a phase 2 trial in alcohol use disorder (NCT06817356), which had not published by late October 2026. No Lilly-sponsored phase 3 trial of mazdutide was listed.

How does mazdutide fit into the pipeline?

Of the GLP-1/glucagon dual agonists covered on this site, mazdutide is the only one with an approval anywhere. That makes it a reference point for survodutide, whose phase 3 obesity results were published in 2026, and for the triple agonist retatrutide. Where each candidate stands is tabulated in the 2026 incretin pipeline overview. Two other late-stage designs take different routes to the same end: amycretin adds amylin receptor activity instead of glucagon, and MariTide blocks the GIP receptor.

NovaEvum does not carry mazdutide. Nothing here is medical, dosing, or therapeutic guidance.

Frequently asked questions

Is mazdutide approved? Yes, in China only, as far as this article could confirm. It was approved there for long-term weight management in June 2025 and for glycaemic control in type 2 diabetes in September 2025. No approval by the FDA, the EMA or Health Canada was found. It remains investigational everywhere else.

How much weight did people lose on mazdutide? In GLORY-1, Chinese adults with overweight or obesity had mean weight change of −11.0% and −14.0% at 48 weeks on two dose levels, against +0.3% on placebo. In GLORY-2, at a higher dose level, it was −16.65% at 60 weeks against −1.50%. These are results from Chinese populations.

Is mazdutide better than semaglutide? That has not been shown. The head-to-head trial against semaglutide in type 2 diabetes, DREAMS-3, is listed as completed but had not published results by late October 2026. Against dulaglutide in DREAMS-2, mazdutide lowered HbA1c modestly more and weight several percentage points more.

What are the side effects of mazdutide? Mainly gastrointestinal. In GLORY-2, vomiting affected 53.1% of mazdutide recipients against 1.3% on placebo, nausea 46.9% against 3.2%, and diarrhoea 39.4% against 6.5%, mostly mild to moderate. In the US phase 2 trial, 20% at the highest dose level stopped because of adverse events.

Who makes mazdutide? It is developed by Eli Lilly, under the code LY3305677, together with Innovent Biologics, which ran the Chinese GLORY and DREAMS phase 3 trials as IBI362. Lilly sponsored the US phase 2 trial. In China it is marketed under the brand name Xinermei.

Selected Research References

  1. Shirley M. Mazdutide: First Approval. Drugs. 2025;85:1621-1627. pubmed.ncbi.nlm.nih.gov/41028652
  2. Ji L, Jiang H, Bi Y, et al. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. New England Journal of Medicine. 2025;392:2215-2225. pubmed.ncbi.nlm.nih.gov/40421736
  3. Gao L, Jiang H, Cai H, et al. Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial. JAMA. 2026;336:377-388. pubmed.ncbi.nlm.nih.gov/42251595
  4. Hsia SH, Bays HE, Billings LK, et al. Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial. The Lancet Diabetes & Endocrinology. 2026;14:879-893. pubmed.ncbi.nlm.nih.gov/42628555
  5. Zhu D, Zhao J, Cai H, et al. Mazdutide versus placebo in Chinese adults with type 2 diabetes. Nature. 2026;652:174-180. pubmed.ncbi.nlm.nih.gov/41407859
  6. Guo L, Zhang B, Xue X, et al. Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes. Nature. 2026;652:181-188. pubmed.ncbi.nlm.nih.gov/41407860
  7. Luo Y, Jiang H, Shi B, et al. Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial. Contemporary Clinical Trials. 2026;160:108150. pubmed.ncbi.nlm.nih.gov/41260459
  8. Kushner PR, Michos ED. Cardiovascular Effects of Glucagon Receptor Signaling Alone and Combined With Glucagon-Like Peptide-1 Receptor Signaling in Multiagonists: A Narrative Review With a Translational Focus. Journal of the American Heart Association. 2026;15:e049727. pubmed.ncbi.nlm.nih.gov/42535526

All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.